Ebglyss (lebrikizumab) Coverage Criteria
Customize your policy alerts
Sign up for Molina Healthcare Policy C29044-A alerts
Get alerted when Policy C29044-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and continuation coverage for Ebglyss (lebrikizumab-lbkz) in members aged 12 years and older with moderate-to-severe atopic dermatitis, including clinical eligibility, treatment history, documentation, dosing, administration, and Illinois-specific requirements.
The Q3 2026 revision history identifies quantity and reference updates.
The Q2 2026 revision history identifies revisions to required medical information and the duration of approval.
The Q3 2025 revision history identifies revisions to required medical information, exclusions/discontinuation, other special considerations, available dosage forms, and references.
The policy was created with new criteria in Q1 2025.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.